Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

被引：0
|
作者：
Eric S. Daar [1 ]
Chloe Orkin [2 ]
Paul E. Sax [3 ]
Debbie Hagins [4 ]
Anton Pozniak [5 ]
Kimberly Workowski [6 ]
Cynthia Brinson [7 ]
Juan Manuel Tiraboschi [8 ]
Hui Liu [9 ]
Chris Deaton [10 ]
Cal Cohen [10 ]
Sharline Madera [10 ]
Jason T. Hindman [10 ]
Moti Ramgopal [10 ]
机构：
[1] Lundquist Institute at Harbor-UCLA Medical Center,
[2] Queen Mary University of London,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Coastal CARE Centers,undefined
[5] Chelsea and Westminster Hospital,undefined
[6] London School of Hygiene and Tropical Medicine,undefined
[7] Emory University,undefined
[8] Central Health,undefined
[9] Hospital Universitari de Bellvitge,undefined
[10] Gilead Sciences,undefined
[11] Inc.,undefined
[12] Midway Research Center and Midway Specialty Care Center,undefined
来源：
AIDS Research and Therapy | / 22卷 / 1期
关键词：
Antiretroviral therapy; Bictegravir; Body mass index; Dolutegravir; Glucose; HIV-1; Tenofovir alafenamide;
D O I：
10.1186/s12981-025-00732-w
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
    Ciccullo, Arturo
    Baldin, Gianmaria
    Sterrantino, Gaetana
    Madeddu, Giordano
    D'ettorre, Gabriella
    Mussini, Cristina
    Di Giambenedetto, Simona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (07) : 1808 - 1809
  • [32] Bictegravir/emtricitabine/ tenofovir alafenamide versus other regimens for initial therapy in late presenters with AIDSdefining conditions
    Perez Valero, I.
    Corona, D.
    Camacho, A.
    Gutierrez Liarte, A.
    Montero Alonso, M.
    Aleman, M. R.
    Ruiz Seco, P.
    Perez Gonzalez, A.
    Riera, M.
    Rivero-Juarez, A.
    Rivero, A.
    HIV MEDICINE, 2023, 24 : 677 - 678
  • [33] Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
    Mendoza, Ines
    Lazaro, Alicia
    Espinosa, Alfredo
    Sanchez, Lorenzo
    Horta, Ana Maria
    Torralba, Miguel
    PLOS ONE, 2023, 18 (09):
  • [34] Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
    Rolle, Charlotte-Paige
    Castano, Jamie
    Nguyen, Vu
    Hinestrosa, Federico
    Dejesus, Edwin
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
  • [35] Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
    Gidari, Anna
    Benedetti, Sara
    Tordi, Sara
    Zoffoli, Anastasia
    Altobelli, Debora
    Schiaroli, Elisabetta
    De Socio, Giuseppe Vittorio
    Francisci, Daniela
    INFECTIOUS DISEASE REPORTS, 2023, 15 (06) : 766 - 777
  • [36] Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
    De Socio, Giuseppe Vittorio
    Tordi, Sara
    Altobelli, Debora
    Gidari, Anna
    Zoffoli, Anastasia
    Francisci, Daniela
    Wozniacka, Anna
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [37] Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants
    Lagoutte-Renosi, Jennifer
    Flammang, Mylene
    Ducloux, Didier
    Bamoulid, Jamal
    Royer, Pierre-Yves
    Lepiller, Quentin
    Clairet, Anne-Laure
    Davani, Siamak
    Muret, Patrice
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 199 - 202
  • [38] HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    D'Antoni, Michelle L.
    Andreatta, Kristen
    Chang, Silvia
    Cox, Stephanie
    Hindman, Jason T.
    Avihingsanon, Anchalee
    Martin, Hal
    Vanderveen, Laurie A.
    Callebaut, Christian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (04) : 380 - 384
  • [39] Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up
    Lanzafame, Massimiliano
    Lattuada, Emanuela
    Delama, Andrea
    Mori, Giovanni
    Vento, Sandro
    BIOMEDICINES, 2024, 12 (11)
  • [40] Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
    Januszka, Jenna E.
    Drwiega, Emily N.
    Badowski, Melissa E.
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2023, 15 : 705 - 711
12345